U.S. Computer-Aided Detection (CAD) is the largest market in the world in the global computer-aided detection

 

The market for U.S. computer-aided detection is growing rapidly in the healthcare sector. The growth in the region is attributed to the availability of advanced diagnostic technologies, the widening adoption of CAD systems, and well-established healthcare systems. Some of the key players operating in this market are EDDA Technology, Inc., Hitachi High Technologies Corporation, Hologic Inc., and Toshiba Medical Systems Corporation.

A large study found that implementing computer-aided detection improved small-nodule lung cancer screening rates. However, the study found that this method was associated with lower sensitivity and higher false-positive rates. This study also found that the positive predictive value decreased in facilities that used computer-aided detection. Despite these results, this technique may not be a viable alternative for every patient, as its sensitivity is dependent on other factors.

An increase in recall rates was found in a recent study involving breast cancer screenings. Computer-aided detection (CAD) increased recall rates by 0.3 percentage points compared to double-reading. Its sensitivity was higher compared to the first reader, and the recall rate for single-reading CAD was 1.2 percentage points higher than that of the double-reading method. Despite these differences, both methods had similar overall cancer detection rates.

U.S. Computer-Aided Detection (CAD) Market Size, Share & Analysis, By Application (Neurosurgery Navigation Systems, Orthopedic Navigation Systems, ENT Navigation Systems, Dental Navigation Systems

The area under the ROC curve for CAD and non-CAD has significantly lower specificity. The area under the curves for both methods were 0.871 and 0.919 respectively. Hence, it is possible to improve sensitivity without sacrificing specificity. The findings of this study have important clinical implications. Among the factors that reduce sensitivity are the additional reading time and sphericity setting. The Fenton study is the largest evaluation of CAD in breast cancer screening to date. However, the study failed to adequately account for the time required for physicians to become accustomed to the new technology. It was noted that, on average, sites had been using CAD for seven months before the study began. This delay could have led to an increase in false-positive results, but that study has yet to be replicated.